CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease by Picó, Sara et al.
  
 
 Submitted Manuscript:  Confidential             template updated: February 28 2012 
 
 
CPEB alteration and aberrant transcriptome-polyadenylation unveil a 
treatable SLC19A3 deficiency in Huntington’s disease 
 
Authors:  Sara Picó1,2†, Alberto Parras1,2†, María Santos-Galindo1,2, Julia Pose-Utrilla2,3, 
Margarita Castro1,4,5, Enrique Fraga1,2, Ivó H. Hernández1,2,6, Ainara Elorza1,2, Héctor Anta7,8, 
Nan Wang9, Laura Martí-Sánchez5,10, Eulàlia Belloc8, Paula García-Esparcia2,11, Juan J. 
Garrido2,12, Isidro Ferrer2,11, Daniel Macías-García2,13, Pablo Mir2,13, Rafael Artuch5,10, Belén 
Pérez1,4,5, Félix Hernández1,2, Pilar Navarro7,14, José Luis López-Sendón15, Teresa Iglesias2,3, X. 
William Yang9, Raúl Méndez8,16 and José J. Lucas1,2* 
Affiliations: 
1Center for Molecular Biology “Severo Ochoa” (CBMSO) CSIC/UAM, Madrid 28049, Spain. 
2Networking Research Center on Neurodegenerative Diseases (CIBERNED). Instituto de Salud Carlos III, Madrid, 
Spain. 
3Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad 
Autónoma de Madrid (CSIC-UAM), Madrid, Spain. 
4Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Madrid 28049, Spain. 
5Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain. 
6Facultad de Ciencias, Departamento de Biología (Unidad Docente Fisiología Animal), Universidad Autónoma de 
Madrid, Madrid 28049, Spain. 
7 Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Unidad Asociada I+D+i IMIM- 
IIBB (CSIC), Barcelona, Spain. 
8Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology, 08028 Barcelona, Spain. 
9Center for Neurobehavioral Genetics, Jane and Terry Semel Institute for Neuroscience and Human Behavior; 
Department of Psychiatry and Biobehavioral Sciences; Brain Research Institute, David Geffen School of Medicine at 
UCLA, Los Angeles, CA, 90095, USA. 
10Department of Clinical Biochemistry, Institut de Recerca Sant Joan de Déu, Barcelona, Spain. 
11Institute of Neuropathology; IDIBELL-University Hospital Bellvitge; University of Barcelona; Hospitalet de 
Llobregat; Barcelona 08908, Spain. 
12Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal (CSIC), Madrid, Spain. 
13Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina 
de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla 41013, Spain. 
14Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain. 
15Department of Neurology, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 
Madrid 28034, Spain. 
16Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain. 
 
*To whom correspondence should be addressed: 
   José J. Lucas 
   jjlucas@cbm.csic.es 
   Center for Molecular Biology-Severo Ochoa (CBMSO)  
   C/ Nicolás Cabrera,1. 28049 Madrid. Spain 
   Tel.  +34 91 196 4552 
    http://www.cbm.uam.es/LucasLab 
† These authors contributed equally 
 
One Sentence Summary: Altered CPEBs and mRNA-poly(A) unveil a BTBGD-like   




Huntington’s disease (HD) is a devastating hereditary neurodegenerative disorder of the basal 
ganglia for which disease-modifying treatments are not available. Although promising gene-
silencing therapies are currently being tested, new molecular mechanisms underneath the 
triggering mutation must be explored to identify easily druggable targets. Cytoplasmic 
polyadenylation element binding proteins 1–4 (CPEB1–4) are RNA-binding proteins that repress 
or activate translation of CPE-containing transcripts by, respectively, shortening or elongating 
their poly(A) tail. Here we report increased CPEB1 and decreased CPEB4 protein levels in 
striatum of HD patients and mouse models. This correlates with a reprogramming of 
polyadenylation in 17.3% of the transcriptome that markedly affects neurodegeneration-associated 
genes (like PSEN1, MAPT, SNCA, LRRK2, PINK1, DJ1, SOD1, TARDBP, FUS and HTT), thus 
suggesting a new molecular mechanism in neurodegenerative disease aetiology. Besides, we found 
decreased protein levels of top deadenylated transcript-genes which include striatal atrophy-linked 
genes not previously related to HD such as KTN1 and, remarkably, the easily druggable SLC19A3 
(ThTr2 thiamine transporter). Mutations in SLC19A3 cause biotin-thiamine-responsive basal 
ganglia disease (BTBGD), a devastating striatal disorder that however reverts upon a vitamin-
based therapy. Decreased ThTr2 in HD led to discover that, alike BTBGD patients, HD patients 
show decreased CSF thiamine levels. Furthermore, HD patients and mice show decreased striatal 
concentrations of TPP, the metabolically active form of thiamine. Remarkably, a high dose 
biotin+thiamine treatment used to revert BTBGD prevented the TPP deficiency of HD mice and 
attenuated their radiological, neuropathological and motor HD-like phenotypes, thus unveiling an 





Huntington’s disease (HD) is a devastating hereditary neurodegenerative disorder 
characterized by atrophy of the basal ganglia, particularly the striatum, and prominent motor 
symptoms (1). The underlying mutation is an expanded CAG repeat in the Huntingtin (HTT) gene, 
which codes for a self-aggregating polyglutamine (polyQ) tract in the N-terminal region of the 
protein (1). Although HTT lowering strategies currently in clinical trials are promising therapeutic 
strategies (2), they may be challenged by limitations associated to efficacy of delivery to the basal 
ganglia and side effect issues (3). It is therefore important to keep elucidating the molecular 
mechanisms by which the triggering mutation elicits its toxicity as a way to find easily druggable 
targets. 
Similar polyQ-encoding CAG mutations in different genes cause spinal-bulbar muscular 
atrophy (SBMA), dentatorubral-pallidoluysian atrophy (DRPLA) and multiple dominant 
spinocerebellar ataxias (SCAs) such as SCA-1, -2, -3, -6, -7 or -17 (4) and there is evidence of 
toxicity being mediated by both the expanded CAG-containing mRNAs and the polyQ-containing 
proteins (5, 6). Interestingly, one of the few genes able to act as a dual modifier of the toxicities 
induced by either CAG-repeat mRNA or polyQ in Drosophila models of SCA-3 is Orb2 (6), the 
orthologue of mammalian CPEB2-4. 
Cytoplasmic polyadenylation element binding proteins 1–4 (CPEB1–4) are RNA binding 
proteins that recognize transcripts that harbor CPE sequences in their 3’UTR -approximately 40% 
of the transcriptome (7, 8)- and that repress or activate their translation by inducing shortening or 
elongation of their poly(A) tail (9). This CPEB-dependent regulation of transcriptome 
polyadenylation occurs in the cytoplasm and confers an additional layer of post-transcriptional 
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regulation of gene expression (9, 10). CPEBs play a key role in early development (9) and they 
also act in adult neurons to enable synaptic plasticity through prion-like mechanisms (9, 11). 
Altered CPEBs and subsequent alteration in transcriptome polyadenylation have been 
associated to the aetiology of various diseases such as cancer (12, 13), chronic liver disease (14), 
epilepsy (15) or autism (8), thus leading to the identification of new possible therapeutic targets 
among CPEB-dependent dysregulated genes. However, a potential role of CPEBs in 
neurodegenerative disorders has not been fully explored.  
Interestingly, we noticed that HD-related genes are prevalent among genes that are 
mistranslated in the absence of CPEB1 (16). This, together with the mentioned ability of CPEBs 
to modulate CAG/PolyQ toxicity in flies (6), led us to characterize the status of CPEBs and of 
global mRNA-polyadenylation in HD as a way to deepen on the molecular pathogenesis of HD 
and to explore new possible therapeutic targets. 
 
Results  
CPEB1/4 imbalance in HD striatum 
To explore the status of CPEBs in HD we performed Western blot analysis on post-mortem striatal 
tissue from HD cases and control subjects. This revealed markedly increased CPEB1 (303%, 
P=610–3) and markedly decreased CPEB4 (51%, P=1.410–5) protein levels in HD striatum (Fig. 
1A), while no significant changes were observed regarding CPEB2 or CPEB3 (fig. S1A). We then 
explored whether a similar alteration of CPEBs takes place in mouse models of HD. We first 
analysed the widely used R6/1 mouse model which overexpresses exon1-mutant Htt thus resulting 
in a robust, yet slowly-progressing, motor phenotype. Similar to human samples, striatal 
homogenates from R6/1 mice showed increased CPEB1 and decreased CPEB4 protein levels (Fig. 
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1B) without changes in CPEB2 or CPEB3 (fig. S1B). Next, we analysed zQ175 mice, a 
heterozygous knock-in HD model with CAG expansion in the endogenous Htt gene which better 
resembles the human HD mutation, but that does not develop an overt motor phenotype within the 
maximal (approximately 2.5 years) lifespan of a mouse. In this model of pre-manifest HD, we only 
observed the decrease in striatal CPEB4 protein levels (fig. S1C) thus suggesting that the decrease 
in CPEB4 levels observed in HD patients and R6/1 mice precedes the increase in CPEB1. 
To test whether the marked CPEB1/CPEB4 protein imbalance in symptomatic HD patients 
and mice is due to matching changes at transcript level, we then performed RT-PCR analysis (fig. 
S1, D and E). Regarding CPEB1, we observed a tendency to increased transcript level in human 
HD striatum and a significant increase in R6/1 striatum that might account for the increased 
CPEB1 protein levels. Regarding CPEB4, mRNA levels were unaltered in HD and R6/1 striatum, 
thus suggesting that the observed decreased CPEB4 protein levels are likely due to 
posttranscriptional mechanisms. In this regard, and given the ability of CPEBs to act as 
physiological prions (11, 17), we performed immunohistochemistry of CPEB4 in R6/1 mice to test 
whether the decrease in soluble CPEB4 was due to sequestration into the characteristic nuclear 
inclusion bodies. However, R6/1 mice showed homogeneous decrease of the cytoplasmic neuronal 
CPEB4 staining (Fig. 1C) without co-localization with the Htt-positive intranuclear inclusions 
(Fig. 1D). In summary, these results demonstrate that CPEBs are altered in HD with CPEB1 being 
increased and CPEB4 decreased in striatum of symptomatic HD patients and mice. 
 
CPEB4 overexpression attenuates HD-like motor phenotype 
To explore whether the observed alterations in CPEBs are likely contributors to HD pathogenesis, 
we decided to perform mouse genetics analysis. For this, we took advantage of previously 
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generated CPEB1-deficient (CPEB1 heterozygous KO, CPEB1+/-) (14) and CPEB4 
overexpressing (CamkII-tTA:TRE-CPEB4, TgCPEB4) (8) mice. These mice were bred with R6/1 
mice to test whether attenuation of the excess CPEB1 or of the decreased CPEB4, results in 
amelioration of the R6/1 HD-like motor phenotype. We found that R6/1:CPEB1+/- mice perform 
very similar to R6/1 mice in the tests that detect HD-associated impaired motor coordination and 
hypolocomotion, the rota-rod and the open field tests, respectively (Fig. 2, A and B). The 
R6/1:CPEB1+/- mice even show a tendency to worse performance in the inverted grid test that 
detects deficits in limb strength (Fig. 2C). Regarding CPEB4 overexpressing mice, 
R6/1:TgCPEB4 mice show a significant attenuation of the motor coordination deficit observed in 
the rotarod (Fig. 2D) and a tendency to less hypoactivity in the open field, as compared to R6/1 
mice (Fig. 2E). A slight tendency to better performance in the inverted grid test was also observed 
for R6/1:TgCPEB4 mice (Fig. 2F). Altogether, and in good agreement with the ability of Orb2 to 
act as a modifier of CAG/polyQ toxicity in fly models (6), these results indicate that CPEB-
alteration, particularly the decrease in CPEB4, contributes to HD pathogenesis. 
 
Altered transcriptome polyadenylation affects genes linked to major neurodegenerative diseases 
We then tested whether the CPEB-alteration observed in striatum of HD patients and mice 
correlates with changes in transcriptome polyadenylation. For this, we extracted total RNA from 
striatum of R6/1 and wild type mice and performed poly(U) chromatography followed by gene 
chip analysis. This revealed that in R6/1 striatum, transcript poly(A) tail length increased in 8.7%, 
and decreased in 8.6%, of the analysed genes (Fig. 3A; table S1A). Interestingly, we performed 
gene ontology analysis (using KEGG pathways) of the 1,467 genes with absolute poly(A) fold-
change (FC) above 2 and found that the three terms with significant Benjamini–Hochberg 
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corrected P-value were: HD, Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Fig. 3B; 
table S1B). Thus suggesting that altered polyadenylation may contribute to pathogenesis not only 
in HD but also across the main neurodegenerative disorders. In good agreement with this, genes 
playing key roles in neurodegeneration—such as those mutated in familial forms of 
AD/tauopathies, PD or amyotrophic lateral sclerosis (including PSEN1, MAPT, SNCA, LRRK2, 
PINK1, DJ1, SOD1, TARDBP, FUS) and HTT itself—showed altered polyadenylation (Fig. 3C 
and table S1A). Interestingly, this may explain why some of the neurodegeneration-related genes, 
such as MAPT and GSK3B, have been reported to display detrimental altered protein levels in 
brains of HD patients and mice without matching alterations at the transcript level (18, 19). In 
summary, we have found that the striatum of symptomatic HD mice shows an alteration of poly(A) 
tail length in 17.3% of the transcriptome that markedly affects neurodegeneration associated genes, 
thus suggesting a new molecular mechanism in the aetiology of HD and possible also in other 
major neurodegenerative diseases. 
 
Top deadenylated genes include striatal atrophy-linked genes and show decreased protein levels 
Interestingly, we analysed the presence of CPE sequences in the UTR of the genes showing altered 
polyadenylation and we observed an enrichment selectively in the genes showing deadenylation 
(Fig. 4A). Strikingly, among the most markedly deadenylated genes (FC <–4.0), the percentage of 
CPE-containing genes was 93% (Fig. 4B). Shortening of the poly(A) tail is associated to 
diminished translation and decreased protein levels (20), thus suggesting a possible CPEB-
dependent decrease in protein levels of deadenylated transcripts. In fact, we confirmed reduced 
protein levels of top deadenylated genes such as AUTS2, ROCK1 and KTN1 both in HD and R6/1 
striatal tissue, despite unaltered transcript levels (Fig. 4, B and C). Remarkably, decreased KTN1 
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protein levels may be relevant to the striatal atrophy in HD, as a genome-wide association study 
of common variants affecting volume of subcortical regions revealed that the size of the striatum 
is proportional to KTN1 gene expression (21). Also among these top deadenylated (FC <–4) genes, 
extremely interesting regarding both potential causative role in striatal degeneration and 
therapeutic relevance for HD was SLC19A3 (Fig. 4B), because its mutation causes biotin-thiamine-
responsive basal ganglia disease (BTBGD; OMIM #607483), a devastating neural disorder with 
prominent striatal affectation that can however be reverted with a vitamin-based therapy  (22, 23).  
 
HD is a BTBGD-like thiamine deficiency 
SLC19A3 encodes the transmembrane thiamine transporter 2 (ThTr2) (24). Thiamine (vitamin B1) 
is a cofactor for multiple enzymes in the catabolism of sugars (23). Free thiamine from the diet is 
converted in cells to its derivatives, thiamine monophosphate (TMP) and thiamine pyrophosphate 
(TPP) (23). TPP is the bioactive form, acting as an enzyme cofactor (23). Individuals with BTBGD 
have decreased cerebrospinal fluid (CSF) thiamine levels despite normal thiamine levels in blood 
(25, 26), bilateral atrophy in the head of the caudate nucleus and of the putamen as well as a variety 
of neurological symptoms, including lethargy, irritability, dystonia, spasticity, tremor and chorea, 
among others. All these symptoms improve upon administration of thiamine (27) to compensate 
for its decreased transporter and biotin (27) which is believed to increase SLC19A3 transcription 
(28, 29). We therefore hypothesized that HD disease might in part be a phenocopy of BTBGD due 
to a decrease in ThTR2 protein levels. This might therefore provide a new mechanistic clue about 
HD as well as a potential novel therapy. 
Indeed, we next confirmed by Western blot a marked decrease in ThTr2 levels in both 
striatum and cortex of individuals with HD despite a tendency to increased transcript levels (Fig. 
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5A). This was mirrored by strongly decreased staining of the protein by immunohistochemistry in 
both striatum and cortex, which, in good agreement with the human protein atlas (proteinatlas.org), 
revealed neuronal and endothelial localization (Fig. 5B). More importantly, in the CSF of 
individuals with HD, we observed decreased levels of TMP (the prevailing form of thiamine in 
CSF), despite unaltered blood levels of thiamines (Fig. 5C), thus resembling what has been 
reported for individuals with BTBGD (25, 26).  In brain tissue, the cofactor TPP is the predominant 
form of thiamine (30) and it is assumed that CSF thiamine deficiency in BTBGD patients correlates 
with decreased brain levels of the intracellular cofactor, ultimately leading to neuronal 
dysfunction. To our knowledge, no data on brain TPP levels are available regarding BTBGD 
patients. However, we were able to test this in post-mortem samples of HD striatum. Strikingly, 
we found a marked decrease in TPP concentrations in HD striatal tissue (Fig. 5D). Altogether, 
these results demonstrate a thiamine deficiency in HD brain and suggest that individuals with HD 
might benefit from thiamine and/or biotin supplementation therapy, as is seen for individuals with 
BTBGD. 
 
High biotin+thiamine improves radiology, neuropathology and motor phenotype of HD mice 
In order to pre-clinically test the potential of vitamin supplementation for HD, we first confirmed 
that HD mice also show decreased ThTr2 levels. In the mouse, Slc19a3 transcript expression is 
essentially restricted to brain endothelium (vastdb.crg.eu), and we observed that ThTr2 protein 
was almost absent from the brain vessels isolated from R6/1 mice (fig. S2A) and markedly reduced 
in those from zQ175 mice (fig. S2B). We then tested whether HD mice also show reduced striatal 
concentration of TPP and, importantly, whether this would revert upon a regime of high dose biotin 
and thiamine treatment like the one used in BTBGD patients. We found that both zQ175 and R6/1 
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mice do show decreased striatal concentration of TPP (Fig. 6, A and B). Importantly, we found 
that the combined therapy of biotin and thiamine in the drinking water (B+T, see Methods) 
prevented the decreased striatal content of TPP in both zQ175 and R6/1 mice (Fig. 6, A and B). 
As mentioned, symptoms of individuals with BTBGD ameliorate with high doses of biotin 
considerably exceeding the adequate intake needs (27, 31) -presumably through increased 
SLC19A3 transcription (28, 29)-, with thiamine supplementation, and with combinations of both 
(27).  Thus, we tested whether the B+T treatment that normalizes TPP levels in striatum of HD 
mice was also able to improve their HD-like phenotypes. Although zQ175 mice do not show an 
overt motor phenotype, they do display striatal atrophy and phosphocreatine spectroscopy 
alteration (32). We performed magnetic resonance imaging (MRI) on untreated 17-week old 
zQ175 mice to verify striatal atrophy (Fig. 6C) and on treated and untreated 24-week old zQ175 
mice to test the possible efficacy of B+T treatment on the striatal atrophy. We found that the B+T 
treatment prevented the additional striatal atrophy experienced by untreated zQ175 mice and it 
even showed a tendency to slightly revert the decrease in striatal volume observed in untreated 17 
week-old zQ175 mice (Fig. 6D). Similarly, the increase in striatal phosphocreatine signal seen in 
zQ175 mice by magnetic resonance spectroscopy (MRS), was prevented by B+T treatment (Fig. 
6E). 
We then tested the effect of B+T treatment on the overt motor phenotype and 
neuropathology of R6/1 mice. We found that the motor coordination deficit detected with the 
rotarod test in 13 week- and 18 week-old R6/1 mice was prevented by the B+T treatment (Fig. 
6F). Similarly, the deficit in limb strength detected in the inverted grid test at the ages of 18 and 
23 weeks was also prevented by the B+T treatment (Fig. 6G). Finally, we measured the striatal 
area and number of apoptotic (cleaved-caspase 3-positive) neurons in coronal sections of 4.5 
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month-old R6/1 mice and found that the B+T treatment prevented both the striatal atrophy (Fig. 
6H) and the increased number of apoptotic neurons (Fig. 6I). Together, these results, demonstrated 
that a B+T treatment similar to the one that ameliorates BTBGD patients is able to prevent the 
brain thiamine deficiency observed in HD mice and to attenuate their radiological, 
neuropathological and motor HD-like phenotypes, thus evidencing that HD patients might benefit 





By analysing the status of CPEBs and of global transcriptome polyadenylation in brains of 
HD patients and mouse models, here we report a pathogenic decrease of CPEB4 as well as an 
increase in CPEB1 protein levels that correlate with altered polyadenylation of neurodegeneration 
linked genes, thus unveiling a new molecular mechanism in neurodegenerative disease. Besides, 
Western blot analysis of CPE-containing deadenylated transcripts allowed us to identify new key 
striatal atrophy effector genes such as KTN1 and, more importantly, SLC19A3. The latter led us 
to discover that HD is in part a thiamine deficiency disorder similar to BTBGD, thus unveiling an 
easy to implement vitamin-based therapy for HD, as evidenced by the also reported behavioural 
and neuroanatomical improvement of HD mice upon biotin and thiamine supplementation. 
HTT gene silencing strategies were pre-clinically proven effective in animal models (33-
35) and this led to the development of therapies designed to lower HTT gene expression in HD 
patients that are currently in clinical trials (36, 37) and that are very attractive because they target 
the root cause of the disease. However, such HTT-lowering gene therapies may encounter 
difficulties associated to invasive modes of delivery -often requiring repeated dosage- and to 
limited coverage of the CNS, among others (3). It is therefore important to keep in mind that there 
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is currently no disease modifying therapy for HD. In this context, the main implication of our study 
is that it unveils a trivial therapy that is expected to ameliorate the course of the disease and that 
deserves soon clinical testing. 
That biotin and thiamine supplementation may ameliorate the course of the disease in HD 
patients is evidenced by the fact that we have demonstrated that HD is a BTBGD-like brain 
thiamine deficit in which the underlying ThTr2 deficiency is caused by decreased SLC19A3 
expression (instead of the SLC19A3 inactivating mutations that cause BTBGD). Since BTBGD 
patients recover upon early biotin and thiamine supplementation, HD patients should also improve, 
particularly if treated early enough. However, although correcting this undoubtedly-pathogenic 
thiamine deficiency is expected to delay the course of the disease -as seen in R6/1 mice-, we should 
keep in mind that other aspects of the toxicity triggered by expanded CAG-repeat RNA and/or 
expanded polyQ will not be solved. In any case, given the parallelism with BTBGD, the combined 
biotin and thiamine therapy is expected to significantly improve quality of life of patients for some 
time. 
Importantly, the biotin and thiamine supplementation therapy has multiple advantages such 
as safety and full accessibility to CNS. Regarding safety, both biotin and thiamine are natural 
vitamins and, accordingly, they are considered nutraceuticals which are FDA-approved, even at 
high doses in the case of thiamine  (https://ods.od.nih.gov/).  Besides, safety of the combined high 
dose of both vitamins has already been reported for BTBGD patients (27). Another advantage of 
this therapy is its low cost. This, together with easy over-the-counter accessibility, may however 
become a double edge sword at the time of clinical testing. Placebo controlled double bind clinical 
trials should be efficiently launched in the short term to prevent self-prescription to obscure 
interpretation of clinical trials, including those aiming to test other therapeutic agents. Government 
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and non-profit organizations may be key to enable efficient clinical testing of this low cost therapy. 
Still, the patented use of the specific combined therapy for HD may also make it attractive for 
pharmaceutical companies. 
Apart from SLC19A3, this study may lead to the identification of additional therapeutic 
targets, such as those that are expected to be mechanistically upstream. Correlative evidence, 
including the observed phenotypic improvement of mice upon transgenic overexpression of 
CPEB4, strongly suggests that alteration of CPEBs -and remarkably the decreased CPEB4-, leads 
to aberrant polyadenylation and subsequent altered protein levels of numerous aetiology-relevant 
genes. Then, theoretically, therapeutic strategies aimed to correct the decreased CPEB4 protein 
levels might lead to amendment of pathogenic gene mis-expression globally. However, actual 
demonstration of the mentioned mechanistic causality is beyond the scope of this study and, 
besides, the pharmacological modulation of CPEB activity is a challenging issue, particularly to 
counteract decreased levels and/or activity. Therefore, at this point, therapeutic strategies aiming 
to increase CPEB4 levels and/or activity do not seem realistic. A more efficient strategy to identify 
additional therapeutic targets from this study would be to perform a systematic screening of all the 
neurodegeneration-associated deadenylated transcripts to see which ones are easily druggable to 
then verify altered proteins levels in HD patients and mouse model tissue prior to preclinical testing 
in mouse models, similar to what we have already done for SLC19A3. 
In summary, this study reveals that alteration of CPEBs and of global mRNA 
polyadenylation emerges as a new possible molecular mechanism in neurodegeneration. Most 
importantly, this study has pinpointed diminished ThTr2 levels as a key pathogenic effector and 
unveiled a brain thiamine deficiency in HD patients, thus evidencing that vitamin supplementation 




Materials and Methods 
 
Study design. The objectives of this controlled laboratory study were (i) investigate the CPEB and 
polyadenylation status in HD and HD mice, (ii) analyse global mRNA polyadenylation in HD 
using the R6/1 mice HD model, (iii) study the status of SLC19A3 and thiamine in HD and (iv) 
determine whether biotin+thiamine treatment would alleviate HD pathology in HD mouse models. 
Sample size was determined by availability and previous experience with biochemical and 
behavioural experiments in the mouse model. A minimum of three individuals (human/mice) per 
group were used for studies involving statistical analyses, and the n for individual experiments is 
indicated in the figures. Treated/no-treated mice (see Mouse biotin and thiamine treatments) were 
randomly allocated to experimental and control groups at weaning. Blinding was performed during 
data collection and analysis. Outliers were excluded using SPSS 26.0 (see Data analysis). For all 
human studies, sampling was approved by the local ethics committee, and all subjects signed 
informed consent. For mouse studies, all experiments were performed according to the guidelines 
of the Animal Ethics Committee and were approved by the government authorities. 
Human tissue samples. Human tissue samples used in immunoblot and immunohistochemistry 
(IHC) were provided by the Institute of Neuropathology Brain Bank (HUBICO-IDIBELL, 
Hospitalet de Llobregat, Spain), the Neurological Tissue Bank of the IDIBAPS Biobank 
(Barcelona, Spain), the Banco de Tejidos Fundación Cien (BT-CIEN, Madrid, Spain) and the 
Netherlands Brain Bank (Amsterdam, The Netherlands). Written informed consent for brain 
removal after death for diagnostic and research purposes was obtained from brain donors and/or 
next of kin. 
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Cerebrospinal fluids (CSF) were collected in sterile tubes. Total blood was collected in 
K2E (EDTA) tubes (368801, BD Biosciences). CSF and blood were collected according to 
Hospital Universitario Ramón y Cajal (Madrid, Spain), Hospital Universitario Virgen del Rocío 
(Sevilla, Spain) and HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-
Red de Biobancos PT13/0010/0056) guidelines. 
Animals. Different mouse models were used, which have been previously reported: R6/1 
transgenic mice for the human exon-1-Htt gene (38) in B6CBAF1 background, heterozygous 
knock-in of an expanded CAG track in exon 1 of huntingtin gene, zQ175 mice (32) in C57BL/6J 
background, CPEB1-deficient mice (CPEB1 heterozygous KO, CPEB1+/-) (14) in C57BL/6J 
background and CPEB4 overexpressing mice (CamkII-tTA:TRE-CPEB4, TgCPEB4) (8) in 
C57BL/6J background. All mice were housed in CBMSO animal facility, with four per cage. Food 
and water were available ad libitum, and mice were maintained in a temperature-controlled 
environment on a 12/12 h light-dark cycle with light onset at 08:00. Thiamine content in chow diet 
was 7 mg/kg of food pellets, according to the manufacturer (SAFE 150, from Safe-diets, France). 
Animal housing and maintenance protocols followed the local authority guidelines. Animal 
experiments were performed under protocols approved by the CBMSO Institutional Animal Care 
and Utilization Committee (Comité de Ética de Experimentación Animal del CBMSO, CEEA-
CBMSO), and Comunidad de Madrid PROEX 293/15. 
Mouse biotin and thiamine treatments. Treatment based on thiamine and/or biotin was 
administered orally in the drinking water, serving as a control of treatment mice with normal 
drinking water and as a control of genotype non-transgenic litter siblings. 
In R6/1 mice, treatment began at 3 weeks of age, just after weaning. Biotin-only treatment 
consisted of a dose of 10 mg/kg/day; thiamine-only treatment started at a dose of 200 mg/kg/day, 
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which was decreased to 50 mg/kg/day from 18 weeks; and combined biotin and thiamine (B+T) 
treatment consisted of a dose of 5 mg/kg/day of biotin + 100 mg/kg/day thiamine, which was 
reduced to 25 mg/kg/day at the age of 18 weeks. The reason for decreasing thiamine doses from 
week 18 is that in a pilot group of mice in which the dose was not reduced, a possible toxicity in 
R6/1 mice was detected from 24 weeks of age, evidenced by an increase in the volume of drink 
consumed and of urination. These effects were not observed if thiamine concentrations were 
reduced to a quarter of the initial concentration.  Biotin-only and thiamine-only treatments were 
analysed in the pilot experiment, and no attenuation of the phenotype was observed in the motor 
coordination test (Rotarod) or in the locomotor activity test (Open Field) (data not shown). In the 
case of zQ175 mice, B+T treatment consisted of 5 mg/kg/day biotin + 100 mg/kg/day thiamine. 
The number of animals included in each group is indicated in the results section. 
Gene ontology analysis. Transcripts with changes in their poly(A) tail length in St of symptomatic 
R6/1 mice (FC ≤ -2 or ≥ 2) were analysed with DAVID Bioinformatics Resources 6.7, KEGG 
pathway annotation (39). 
Analysis of CPE sequences. 3’UTR (untranslated region) sequences from selected gene sets were 
extracted from Ensembl (http://www.ensembl.org/) and incidence of canonical and functional CPE 
(cytoplasmic polyadenylation element) sequences was detected using the algorithm described 
previously (7) (http://genome.crg.es/CPE/). 
Western blot. Samples from human brain were stored at –80C and ground with a mortar in a 
frozen environment with liquid nitrogen to prevent thawing of the samples, resulting in tissue 
powder. For mouse, brains were quickly dissected on an ice-cold plate and the different structures 
stored at –80C. Human and mouse extracts were prepared by homogenizing the brain areas in ice-
cold extraction buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 
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mM sodium orthovanadate, 1 μM okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-
glycerophosphate, 5 mM EDTA and protease inhibitors (Complete, Roche, Cat. No 
11697498001). Homogenates were centrifuged at 15000g for 15 min at 4C. The resulting 
supernatant was collected, and protein content determined by Quick Start Bradford kit assay (Bio-
Rad, 500-0203). Between 10 and 20 μg of total protein were electrophoresed on 10% SDS-
polyacrylamide gels, transferred to a nitrocellulose blotting membrane (Amersham Protran 0.45 
μm, GE Healthcare Life Sciences, 10600002) and blocked in TBS-T (150 mM NaCl, 20 mM Tris–
HCl, pH 7.5, 0.1% Tween 20) supplemented with 5% non-fat dry milk. Membranes were incubated 
overnight at 4C with the primary antibody in TBS-T supplemented with 5% non-fat dry milk, 
washed with TBS-T and next incubated with secondary HRP-conjugated anti-mouse IgG (1:2000, 
DAKO, P0447) or anti-rabbit IgG (1:2000, DAKO, P0448) and developed using the ECL detection 
kit (PerkinElmer, NEL105001EA). Images were scanned with a densitometer (Bio-Rad, GS-900) 
and quantified with Image Lab 5.2 (Bio-Rad). 
Antibodies: Rabbit CPEB1 (1:350, Santacruz, sc-33193); rabbit CPEB2 (1:1000, Abcam, 
ab51069); rabbit CPEB3 (1:1000, Abcam, ab10883); rabbit CPEB4 (1:1000, Abcam, ab83009); 
rabbit AUTS2 (1:750, Sigma, HPA000390); rabbit KTN1 (1:1000, Proteintech, Cat. 19841-1-AP); 
rabbit ROCK1 (1:1000, Abcam, ab45171); rabbit SLC19A3 (1:1000, Sigma, HPA038898); rabbit 
SLC19A3 (1:1000, Proteintech, 13407-1-AP); mouse β-actin (1:25000, Sigma, A2228); rabbit 
vinculin (1:1000, Abcam, ab129002). 
Poly(U) chromatography. Wild-type and R6/1 mice (n = 4) were sacrificed by cervical dislocation 
at the age of 7-8 months. Striatum was quickly dissected on an ice-cold plate and the pool of the 
four striata was immersed in ice-cold RNAlater (Sigma, R0901). Striatum pool was homogenized 
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and total RNA was extracted and purified with Ultraspec (Biotecx, BL-10050), frozen and stored 
at -80°C until use.  
The poly(A) RNA fraction was purified by poly(U) chromatography. Poly(U)-agarose 
(Sigma, p8563) was suspended in swelling buffer (0.05 M Tris-HCl, pH 7.5, 1 M NaCl) 35 ml/g, 
incubated overnight at room temperature and loaded into the chromatography column. An aliquot 
of total RNA was stored at –80C (“Input”) and the rest was incubated with sample buffer (0.01 
M Tris-HCl, pH 7.5, 1 mM EDTA, 1% SDS) for 5 min at 65°C and chilled on ice. Binding buffer 
was added (0.05 M Tris-HCl, pH 7.5, 0.7 M NaCl, 10 mM EDTA, 25% [v/v] formamide) and then 
the sample was loaded into the poly(U)-agarose chromatography column (Mobitec, M1002s) and 
incubated for 30 min at room temperature (25°C) with agitation. Next, the column containing the 
sample was washed three times at 25°C and six times at 55°C with washing buffer (0.05 M Tris-
HCl, pH 7.5, 0.1 M NaCl, 10 mM EDTA, 25% [v/v] formamide). The 55°C washes were collected 
and stored at –80C (“short poly(A)-tail fraction”). The remaining poly(A) RNA (“long poly(A)-
tail fraction”) was eluted with elution buffer (0.05 M HEPES, pH 7, 10 mM EDTA, 90% [v/v] 
formamide) at 55°C and stored at –80C. The RNA of the two poly(A) fractions was precipitated 
by adding 1 volume of isopropanol, 1/10th volumes of sodium acetate 3M pH 5.2 and 20 μg of 
glycogen (Sigma, G1767). Samples were incubated at –20°C for 20 min and centrifuged 15 min 
at 14000g at 4°C. Supernatant was removed, and the pellet was washed with 750 μL of ethanol 
and centrifuged at 14000g and 4°C for 5 min. The supernatant was removed and the pellet was air-
dried for 5 min. After RNA was resuspended in 300 μL of nuclease-free water, 300 μL of acid 
phenol:chloroform (5:1) was added. Samples were vortexed and centrifuged for 10 min at 14000 
g at 4°C. 
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RNA was quantified with the Qubit Fluorimeter using the Qubit RNA Hs Assay kit 
(Thermo-Fisher Scientific, Q32852). RNA integrity QC was performed with Agilent Bioanalyzer 
2100, using RNA Nano Assay (Agilent Technologies 5067-1511) and RNA Pico Assay (Agilent 
Technologies 5067-1513).  
cDNA library preparation and amplification were performed according to the 
manufacturer’s instructions (Sigma-Aldrich) for WTA2 kit using as a template from 2 to 5 ng of 
Total RNA. cDNA was amplified for 22 cycles and purified using PureLink Quick PCR 
Purification Kit (Invitrogen, K310001). Amplified cDNA was quantified using a Nanodrop ND-
1000 (Thermo- Fisher Scientific), and 8 µg of cDNA from each sample was fragmented and 
labelled with GeneChip Mapping 250K Nsp assay kit (Affymetrix, 900753) following the 
manufacturer's instructions.  
Hybridization was performed using the GeneAtlas Hyb, Wash and Stain Kit for 3' IVT 
arrays. Samples ready to hybridize were denatured at 96°C for 10 min prior to incubation into 
Mouse MG-430 PM Array Strip (Affymetrix, 901570), the hybridization was performed for 16 h 
at 45°C in the GeneAtlas Hybridization Oven (Affymetrix, 00-0331). Washing and stain steps after 
hybridization were performed in the GeneAtlas Fluidics Station (Affymetrix, 00-0079), following 
the specific script for Mouse MG-430 PM Arrays. Finally, arrays were scanned with GeneAtlas 
Scanner (Affymetrix) using default parameters, and CEL files for bioinformatics analysis were 
generated with the GeneAtlas software (Affymetrix). 
Microarray samples were processed using R (R Development Core Team, 2014) and 
Bioconductor (40). Raw CEL files were normalized using RMA background correction and 
summarization (41). Standard quality controls were performed in order to identify abnormal 
samples (42) regarding: a) spatial artifacts in the hybridization process (scan images and pseudo-
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images from probe level models); b) intensity dependences of differences between chips (MvA 
plots); c) RNA quality (RNA digest plot); and d) global intensity levels (boxplot of perfect match 
log-intensity distributions before and after normalization and RLE plots). Probeset annotation was 
performed using the information available in Affymetrix web page 
(https://www.affymetrix.com/analysis/index.affx) using version na35. 
Expression values were adjusted for technical biases as described in (43),  using a linear 
model and implemented with the R package “limma” (44). For each biological replicate the log2 
fold change was computed between “WASH” and “ELUTED” samples and used to find significant 
differences between WT vs R6/1 mice. Differential expression was performed using a linear model 
with fluidics and amplification batch as covariates. Fold-change value of < –1.5 in at least one 
probe indicated that the transcript is shortened in R6/1 mice; ≥ 1.5, that it is lengthened; and the 
values in between mean no change. If the same transcript showed opposite results for different 
probes, it was considered as not changed. 
Real-time quantitative reverse transcriptase-PCR. Quantification was performed by real-time 
PCR using a CFX 384 Real Time System C1000 Thermal Cycler (Bio-Rad) in combination with 
SsoFast Eva Green (Bio-Rad, CN 172-5204) and 0.25 μM of primer pair was used. Data were 
analysed by GenEx 5.3.7 software (Multid AnaLyses AB). The mRNA levels were normalized 
first relative to total RNA and then relative to the 18S ribosome subunit, β-ACTIN, GAPDH and 
β-TUBULIN gene expression in each sample.  
Human primers 
CPEB1 Forward 5’-ggcagccatcttgaacga-3’ 
Reverse 5’-aagtcacacgaccagaacca-3’ 





CPEB3 Reverse 5’-cgaaagctggcagtgatct-3’ 
CPEB4 Forward 5’-cactgtttccaatggaagatgg-3’ 
Reverse 5’-ggtgaacccaggccactatg-3’ 
AUTS2 Forward 5’-gaagcggagagagtccacct-3’ 
Reverse 5’-tcctgaggcttaagtgctacatc-3’ 
ROCK1 Forward 5’-tcccctcgaacgctttctac-3’ 
Reverse 5’-tgtatttttgaccactttccgga-3’ 
KTN1 Forward 5’-atttcagaaagagagaaagaaataagtgg-3’ 
Reverse 5’-tgttcaactgcatccttcaaaga-3’ 





18S Forward 5’-atccattggagggcaagtc-3’ 
Reverse 5’-gctcccaagatccaactacg-3’ 
β-TUBULIN Forward 5’-ctttgtggaatggatcccca-3’ 
Reverse 5’-gactgccatcttgaggcca-3’ 
 
GAPDH and β-ACTIN (Tataa biocenter, qA-01-0101S, qA-01-0104S) 
Mouse primers 
Cpeb1 Forward 5’-ttatctgcagctcacaacctg-3’ 
Reverse 5’-gcaaaagtacttgaagcagacct-3’ 
Cpeb2 Forward 5’-ctgcagcagaggaactcgta-3’ 
 
Reverse 5’-ggttgctccaaggagactgt-3’ 
Cpeb3 Forward 5’-aaaacccagccccagtct-3’ 
Reverse 5’-gcttggggatctctgagga-3’ 
Cpeb4 Forward 5’-caaatcttattttccaccaaaagg-3’ 
Reverse 5’-catcaatgagagcctgaacaga-3’ 
Auts2 Forward 5’-cctccaggccctagtctctt-3’ 
Reverse 5’-aaggggtcccagtaggatgt-3’ 
Rock1 Forward 5’-gatcccaaatcggaagtgaa-3’ 
Reverse 5’-tcataaaccagggcatcca-3’ 
Ktn1 Forward 5’-ttaaaagctgaagtgcagaaattg-3’ 
Reverse 5’-acctcatgtgcggtagcag-3’ 








Gapdh Forward 5’-ctcccactcttccaccttcg-3’ 
Reverse 5’-cataccaggaaatgagcttgacaa-3’ 
β-Actin Forward 5’-ctaaggccaaccgtgaaaag-3’ 
Reverse 5’-accagaggcatacagggaca-3’ 
β-Tubulin Forward 5’-gacctatcatggggacagtga-3’ 
Reverse 5’-cggctctgggaacatagttt-3’ 
 
Immunohistochemical analyses. Sample preparation. For human samples, formalin-fixed (4%, 24 
h), paraffin-embedded, 5 μm thick sections mounted on superfrost-plus tissue slides (Menzel-
Gläser, 631-9483) were deparaffinized. For mouse samples, left hemispheres were fixed overnight 
in 4% paraformaldehyde, cryopreserved for 72h in 30% sucrose in PBS, included in optimum 
cutting temperature (OCT) compound (Tissue-Tek, Sakura Finetek Europe, ref. 4583), frozen and 
stored at −80 °C until use. 30 µm sagittal sections were cut on a cryostat (Thermo Scientific), 
collected and stored free floating in glycol containing buffer (30% glycerol, 30% ethylene glycol 
in 0.02 M phosphate buffer) at −20 °C.  
Immunohistochemistry. For human sections, peroxidase activity was quenched with 0.3% H2O2 in 
methanol for 30 min, followed by antigen retrieval with 10 mM pH 6.0 citrate buffer heated by 
microwave for 15 min. Mouse sections were washed in PBS, immersed in 0.3% H2O2 in PBS for 
45 min to quench endogenous peroxidase activity and blocked for 1 h in blocking solution (PBS 
containing 0.5% Fetal Bovine Serum, 0.3% Triton X-100 and 1% BSA). Human and mice sections 
were incubated overnight at 4°C with the corresponding primary antibody diluted in blocking 
solution. After washing, sections were incubated first with biotinylated anti-rabbit or anti-mouse 
secondary antibody and then with avidin-biotin complex using the Elite Vectastain kit (Vector 
Laboratories, PK-6101 and PK-6102). Chromogen reactions were performed with 
diaminobenzidine (SIGMAFAST DAB, Sigma, D4293) for 10 min. Mouse sections were mounted 
on glass slides and coverslipped with Mowiol (Calbiochem, Cat. 475904) while human slides were 
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dehydrated and coverslipped with DePeX (Serva). Images were captured using an Axioskop2 plus 
(Zeiss) microscope with an DMC6200 camera (Leica).  
Antibodies: Rabbit SLC19A3 (1:1000, Sigma, HPA038898), Rabbit Cleaved Caspase-3 (1:100, 
Cell Signaling, 9661), Rabbit DARPP32 (1:3000, BD, 611520), Rabbit CPEB4 (1:1000, Sigma, 
HPA038394). 
Immunofluorescence. Mouse sections were selected, washed in PBS and pretreated with 0.1% 
Triton X-100 for 30 min, 1 M glycine for 15 min and blocking solution (1% BSA, 0.3% FBS and 
0.1% Triton X-100) for 1 h. Sections were then incubated overnight at 4 °C with mouse anti-
CPEB4 (1:1500, home-made) and goat anti-huntingtin (1:200, N-18 Santa Cruz, sc-8767) in 
blocking solution.  After washing in PBS, sections were incubated with anti-goat Alexa 555 (1:500, 
ThermoFisher, A-21432) and anti-mouse Alexa 488 (1:500, ThermoFisher, A-21202) for 1 h. 
Finally, sections were mounted on glass slides, coverslipped with Mowiol (Calbiochem, 475904) 
and maintained at 4 °C. 
Quantification of cleaved caspase-3 positive cells. Animals were analysed at the age of 19 weeks. 
The total number of immunopositive cells in three sagittal sections (lateral coordinates 0.72, 1.92 
and 3.00 mm) was quantified per each animal using an Olympus BX41 microscope with an 
Olympus camera DP-70 (Olympus Denmark A/S). Means per genotype or +/- treatment were used 
for statistical comparison. 
Striatal area quantification. Animals were analysed at the age of 19 weeks. The striatal area was 
measured by Darpp32 positive immunostaining in sagittal sections (lateral coordinate 2.64) using 
an Olympus BX41 microscope with an Olympus camera DP-70 (Olympus Denmark A/S). Means 
per genotype or +/- treatment were used for statistical comparison. 
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Mouse brain vessels extraction. Brain microvessels were isolated by a modification of methods 
described previously (45, 46). Wild-type and R6/1 mice (n=5) were killed by cervical dislocation 
and brains were extracted from the skull. The meninges were carefully removed and gray matter 
was minced and homogenized in 5 volumes of Buffer A (mM): 103 NaCl, 4.7 KCl, 1.2 KH2PO4, 
1.2 MgSO4, 15 HEPES, pH 7.4, 10 Glucose and 25 NaHCO3 with a Teflon-glass homogenizer. 
Homogenization was achieved with 6 to 10 upward and downward strokes. The homogenates were 
centrifuged at 3500g for 10 min at 4°C. The pellets were resuspended in 15% dextran (MW = 
79,500). Samples were then centrifuged again for 15 min at 5000g at 4°C. The pellets were 
resuspended in 50 ml of Buffer A and passed over a 180-µm-pore-size nylon net (Merck, 
NY8H04700). Once the vessels were isolated, they were resuspended in extraction buffer (see 
Western blot) and 5x loading buffer (Tris 0.5M pH 6.8, SDS 10%, Glycerol 85%, 2% β-
mercaptoethanol, 0.01% bromophenol blue) and then sonicated in a sonicator (Sartoirus, Labsonic 
M) for 10s, 100% amplitude, cycle 1. 
Thiamine determination. CSF, total blood and striatum samples were collected from mice or 
human. Samples were collected in a light-protected vial and stored at -80C.  Cortex and striatum 
samples were homogenized and protein content determined by Quick Start Bradford kit assay (Bio-
Rad, 500-0203). The concentration of free thiamine and its derivatives (TPP and TMP) were 
analysed by a commercially available kit for Vitamin B1 determination (Chromsystems, Munich, 
Germany), using a high-performance liquid chromatography (HPLC) method for its separation and 
quantification, according to a modified reported procedure (47). Samples were put in an 
autosampler protected from light, and 50 µl were applied with a flow rate of 1.0 ml/min to an 
HPLC system (Agilent Technologies, 1200 Series) equipped with a reversed phase analytical 
column (Agilent, Eclipse Plus C18, 3.5µm, 4.6x150mm) with fluorescence detection (Ex 
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wavelength=375nm; Em wavelength=435nm). Briefly, the mobile phase consisted of linear 
gradient of sodium phosphate buffer (pH 7.0) and methanol. Chromatographic data were processed 
with LC ChemStation software (Agilent Technologies). Finally, the concentration of thiamine 
derivatives was calculated in brain tissue in nmol/g protein and in total blood and CSF in nmol/L. 
Magnetic resonance imaging. Mice were placed into the centre of the volume RF 
(radiofrequency) coil and positioned in the magnet under continuous inhalation anaesthesia via a 
nose cone. A respiratory sensor connected to a monitoring system (SA Instruments, Stony Brook, 
NY) was placed under the abdomen to monitor the rate and depth of respiration. Mice were 
anesthetized with a 2% isoflurane in 1L of oxygen in an induction chamber and the flow of 
anaesthetic gas was constantly regulated to maintain a breathing rate of 50 +/- 20 bpm. Animal 
temperature was maintained at approximately at 37°C by passing warm water through a heat 
exchanger machine into the animal platform. The physiological state of the animals was monitored 
using a Magnetic Resonance Imaging (MRI) compatible small animal gating system by SA 
Instruments (Stony Brook, NY; http://www.i4sa.com/) that controlled the respiratory rate. 
The MRI experiments were performed on a Bruker Pharmascan system (Bruker Medical 
Gmbh, Ettlingen, Germany) using a 7.0-T horizontal-bore superconducting magnet, equipped with 
a 1H selective birdcage resonator of 23 mm and a Bruker gradient insert with 90 mm of diameter 
(maximum intensity 36 G/cm) by the MRI facility at the Instituto de Investigaciones Biomédicas 
"Alberto Sols" (Madrid, Spain). All data were acquired using a Hewlett-Packard console running 
Paravision 5.1 software (Bruker Medical Gmbh) operating on a Linux platform.  
T2-weighted (T2-W) spin-echo images were acquired with a rapid acquisition with 
relaxation enhancement (RARE) sequence in axial orientations and the following parameters: TR 
= 3000 ms, TE = 14,7ms, RARE factor = 8, Av = 6, FOV = 2.3cm, acquisition matrix = 256 × 
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256, slice thickness = 1.00 mm without gap and number of slices = 16.  To calculate the striatum 
volume in mm3, area was measured in all series of images obtained in MRI-T2W for each animal 
using ImageJ software (Wayne Rasband, NIH, Bethesda, MD, USA). 
1H MR spectroscopy study was performed in the striatum region. The in vivo spectroscopy 
protocol used a Point-Resolved Spatially Spectroscopy (PRESS), combined with VAPOR water 
suppression and employed the following parameters: TR = 3000 ms, TE = 35 ms, Av = 128, voxel 
volume = 3 mm3. Before acquisition the automatic shimming procedure FASTMAP (48) was used 
to achieve optimal uniformity of the magnetic field across the voxel volume. All 1H spectra were 
automatically analysed using LC Model version 6.2 OR (Stephen Provencher, Oakville, ON; 
Canada). Means per genotype or +/- treatment were used for statistical comparison. 
Behavioral testing. Rotarod test: Motor coordination was measured in an accelerating rotarod 
apparatus (Ugo Basile). Mice were pre-trained during two days at a constant speed, the first day: 
4 trials of 1 min at 4rpm and the second day: 4 trials of 1 min at 8rpm. On the third day, rotarod 
was set to accelerate from 4 to 40 rpm over 5 min and mice were tested four times. During 
accelerating trials, the latency to fall from the rod was measured. 
Inverted grid test: Muscular strength was examined placing the mice in the center of a wire grid 
that is rotated to an inverted position over 10 s and held steadily 50cm above a padded surface. 
Latency to fall from the grid was measured (maximum: 300 s, two trials). 
Open field test: Locomotor activity was measured in clear Plexiglas® boxes measuring 27.5cm x 
27.5cm, outfitted with photo-beam detectors for monitoring horizontal and vertical activity. 
Activity levels were recorded with a MED Associates’ Activity Monitor (MED Associates, St. 
Albans, VT) and were analyzed with the MED Associates’ Activity Monitor Data Analysis 
v.5.93.773 software. Mice were placed in the center of the open-field apparatus and left to move 
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freely. Data were individually recorded for each animal during 15 min. Ambulatory distance 
walked was measured. 
Data analysis. Statistical analysis was performed with SPSS 26.0 (SPSS® Statistic IBM®). Data 
are represented as Mean ± s.e.m (Standard Error of the Mean) with 95% confidence interval. In 
box plots, box segments show median, 25th and 75th percentiles, whiskers above and below show 
the locations of the minimum and maximum. Higher or lower points (outliers) were plotted 
individually or not plotted. The normality of the data was analyzed by Shapiro-Wilk test (n < 50) 
or o Kolmogorov-Smirnov (n > 50). Homogeneity of variance was analyzed by Levene test.  For 
comparison of two independent groups two-tail unpaired t-Student’s test (data with normal 
distribution), Mann-Whitney-Wilcoxon or Kolmogorov-Smirnov tests (with non-normal 
distribution) was performed. To compare dependent measurements, we used a paired t-test (normal 
distribution) or Wilcoxon signed-rank tests (non-normal). For multiple comparisons, data with a 
normal distribution were analyzed by one way-ANOVA test followed by a Tukey’s or a Games-
Howell’s post-hoc test. Statistical significance of non-parametric data for multiple comparisons 
was determined by Kruskal-Wallis One-way ANOVA test. Enrichment tests were carried out by 
using one-sided Fisher's exact test. A critical value for significance of P < 0.05 was used 
throughout the study. 
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Figures Legends:  
 
Fig. 1. CPEB1/4 imbalance in HD striatum. (A,B) CPEB1 and CPEB4 protein levels in (A) 
control or HD striatum, and (B) wild-type or R6/1 mice striatum. (C) CPEB4 
immunohistochemistry in wild-type or R6/1 mice striatum. (D) CPEB4 (green) and HTT 
(red) immunofluorescence in wild-type or R6/1 mice striatum. (A,B) Two-sided unpaired 
t-test. Graphs show mean ± s.e.m.  
Fig. 2. Attenuation of R6/1 phenotype through CPEB4 overexpression. (A, D) Latency to fall 
off the rotarod for (A) wild-type, CPEB1+/-, R6/1 or R6/1:CPEB1+/- mice and (D) wild-
type, TgCPEB4, R6/1 or R6/1:TgCPEB4 mice. (B, E) Ambulatory distance travelled for 
(B) wild-type, CPEB1+/-, R6/1 or R6/1:CPEB1+/- mice (22 weeks-old) and (E) wild-type, 
TgCPEB4, R6/1 or R6/1:TgCPEB4 mice (18 weeks-old respect to 10 weeks-old). (C, F) 
Latency to fall off the inverted grid test for (C) wild-type, CPEB1+/-, R6/1 or 
R6/1:CPEB1+/- mice (22 weeks-old) and (F) wild-type, TgCPEB4, R6/1 or 
R6/1:TgCPEB4 mice (22 weeks-old). One way-ANOVA followed by Tukey’s post-hoc 
test. Graphs show mean ± s.e.m. 
Fig. 3. Global poly(A) alteration in HD affects neurodegeneration related genes. (A) 
Poly(U) chromatography design and percentage of transcripts with lengthened or 
shortened poly(A) in R6/1 striatum (FC ≤ -1.5 & ≥ 1.5). (B) Gene counts from GO 
analysis of mRNAs with altered poly(A)-tail (FC ≤ -2 & ≥ 2). (C) Venn diagram of 
neurodegenerative disease-related genes with altered poly(A) (FC ≤ -1.5 & ≥ 1.5); 
Mendelian disease–linked genes are shown in bold. (B) Benjamini–Hochberg corrected 
P-value.  
Fig. 4. Top deadenylated transcripts show decreased protein levels. (A) Incidence of CPEs in 
3’UTR according to the mRNA poly(A) change. (B) Symbol, gene name and number of 
CPEs of most deadenylated transcripts in R6/1 mice. (C) AUTS2, ROCK1 and KTN1 
protein and mRNA levels in control or HD striatum, and wild-type or R6/1 mouse 
striatum. (A) One-sided Fisher’s exact-test. (C) Two-tailed unpaired t-test. Graphs show 
mean ± s.e.m. 
Fig. 5. Decreased ThTr2 and thiamine in HD. (A, B) SLC19A3 protein (ThTr2) and mRNA 
levels (A) and ThTr2 immunohistochemistry (B) in control and HD striatum and cortex. 
(C) Quantification of thiamines in control and HD CSF (nmol/L) and whole-blood 
(nmol/L). (D) Quantification of thiamines in control and HD striatum (nmol/g protein). 
Two-tailed unpaired t-test. Graphs show mean ± s.e.m. 
Fig. 6. Attenuation of HD mice phenotype upon biotin+thiamine (B+T). (A, B) 
Concentration of thiamines in striatum (nmol/g protein) of (A) wild-type or zQ175 mice 
with or without B+T and (B) wild-type or R6/1 mice with or without B+T. (C, D) In vivo 
T2-weighted MRI quantification of striatal volume of (C) untreated 17 week-old wild 
type or zQ175 mice and (D) treated and untreated 24 week-old wild type or zQ175 mice. 
(E) Phosphocreatine concentration (left) by MR spectroscopy in striatum of wild-type or 
zQ175 mice with or without B+T (example of spectra on the right). (F) Latency to fall off 
the rotarod for wild-type or R6/1 mice with or without B+T. (G) Latency to fall off the 
inverted grid test for wild-type or R6/1 mice with or without B+T. (H) DARPP32-
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immunostained striatal area in wild-type or R6/1 mice with or without B+T. (I) 
Quantification of Cleaved-caspase3 positive cells in brain of wild-type or R6/1 mice with 
or without B+T. (C) Two-tailed unpaired t-test; (A,B,D,E,F,G,H,I) One way-ANOVA 
followed by Tukey’s post-hoc test. Graphs show mean ± s.e.m. 
 
 
Figure S1. CPEB status in HD and HD mice. (A, B) CPEB2 and CPEB3 protein levels in (A) 
control or HD striatum, and (B) wild-type or R6/1 mice striatum. (C) CPEB1 and CPEB4 protein 
levels in wild-type or zQ175 mice striatum. (D, E) CPEB1 and CPEB4 mRNA levels in (D) 
control or HD striatum, and (E) wild-type or R6/1 mice striatum. Two-tailed unpaired t-test. 
Graphs show mean ± s.e.m. 
 
Figure S2. ThTr2 in HD mice. (A, B) SLC19A3 protein (ThTr2) levels in (A) wild-type or 
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Fig. 1. CPEB1/4 imbalance in HD striatum. (A,B) CPEB1 and CPEB4 protein levels in (A) 
control or HD striatum, and (B) wild-type or R6/1 mice striatum. (C) CPEB4 immunohistochemistry 
in wild-type or R6/1 mice striatum. (D) CPEB4 (green) and HTT (red) immunofluorescence in 
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Fig. 2. Attenuation of R6/1 phenotype through CPEB4 overexpression. (A, D) Latency to fall off the rotarod for (A) wild-type, 
CPEB1+/-, R6/1 or R6/1:CPEB1+/- mice and (D) wild-type, TgCPEB4, R6/1 or R6/1:TgCPEB4 mice. (B, E) Ambulatory distance 
travelled for (B) wild-type, CPEB1+/-, R6/1 or R6/1:CPEB1+/- mice (22 weeks-old) and (E) wild-type, TgCPEB4, R6/1 or 
R6/1:TgCPEB4 mice (18 weeks-old respect to 10 weeks-old). (C, F) Latency to fall off the inverted grid test for (C) wild-type, 
CPEB1+/-, R6/1 or R6/1:CPEB1+/- mice (22 weeks-old) and (F) wild-type, TgCPEB4, R6/1 or R6/1:TgCPEB4 mice (22 weeks-
old). One way-ANOVA followed by Tukey’s post-hoc test. Graphs show mean ± s.e.m.
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Fig. 3. Global poly(A) alteration in HD affects neurodegeneration related genes. (A) Poly(U) chroma-
tography design and percentage of transcripts with lengthened or shortened poly(A) in R6/1 striatum (FC ≤ 
-1.5 & ≥ 1.5). (B) Gene counts from GO analysis of mRNAs with altered poly(A)-tail (FC ≤ -2 & ≥ 2). (C) 
Venn diagram of neurodegenerative disease-related genes with altered poly(A) (FC ≤ -1.5 & ≥ 1.5); Mende-
lian disease–linked genes are shown in bold. (B) Benjamini–Hochberg corrected P-value. 
B Transcripts with shortened p(A)-tail length (FC < -4.0) A
Incidence of CPEs in 3’ UTR
FC Symbol Gene Name n. CPEs 
-5.4 Auts2 Autism susceptibility candidate 2 2
-5.3 Akap10 A kinase (PRKA) anchor protein 10 1
-5.0 Zfp518a Zinc finger protein 518A 5
-5.0 Tcf12 Transcription factor 12 2
-4.9 Zw10 Zw10 kinetochore protein 0
-4.9 Rock1 Rho-associated coiled-coil containing protein kinase 1 4
-4.9 Spcs1 Signal peptidase complex subunit 1 2
-4.7 Lax1 Lymphocyte transmembrane adaptor 1 1
-4.6 Memo1 Mediator of cell motility 1 2
-4.5 Ktn1 Kinectin 1 3
-4.3 Tfrc Transferrin receptor 2
-4.2 Nmd3 NMD3 homolog (S. cerevisiae) 3
-4.1 Slc19a3 Solute carrier family 19, member 3 3
***








n = 17832 1865Total 1858












































n = 7  6 
WT
R6/1































150 * P = 0.031










135 ***P = 1 x 10
-2







n = 7  11 
AUTS2
P = 8 x 10-4
P = 4 x 10-3
Fig. 4. Top deadenylated transcripts show decreased protein levels. (A) Incidence of CPEs in 3’UTR according to the mRNA poly(A) 
change. (B) Symbol, gene name and number of CPEs of most deadenylated transcripts in R6/1 mice. (C) AUTS2, ROCK1 and KTN1 
protein and mRNA levels in control or HD striatum, and wild-type or R6/1 mouse striatum. (A) One-sided Fisher’s exact-test. (C) Two-tailed 
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Fig. 5. Decreased ThTr2 and thiamine in HD. (A, B) SLC19A3 protein (ThTr2) and mRNA levels (A) and 
ThTr2 immunohistochemistry (B) in control and HD striatum and cortex. (C) Quantification of thiamines in 
control and HD CSF (nmol/L) and whole-blood (nmol/L). (D) Quantification of thiamines in control and HD 
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Fig. 6. Attenuation of HD mice phenotype upon biotin+thiamine (B+T). (A, B) Concentration of thiamines in striatum (nmol/g protein) of (A) 
wild-type or zQ175 mice with or without B+T and (B) wild-type or R6/1 mice with or without B+T. (C, D) In vivo T2-weighted MRI quantification of striatal 
volume of (C) untreated 17 week-old wild type or zQ175 mice and (D) treated and untreated 24 week-old wild type or zQ175 mice. (E) Phosphocreati-
ne concentration (left) by MR spectroscopy in striatum of wild-type or zQ175 mice with or without B+T (example of spectra on the right). (F) Latency 
to fall off the rotarod for wild-type or R6/1 mice with or without B+T. (G) Latency to fall off the inverted grid test for wild-type or R6/1 mice with or without 
B+T. (H) DARPP32-immunostained striatal area in wild-type or R6/1 mice with or without B+T. (I) Quantification of Cleaved-caspase3 positive cells in 
brain of wild-type or R6/1 mice with or without B+T. (C) Two-tailed unpaired t-test; (A,B,D,E,F,G,H,I) One way-ANOVA followed by Tukey’s post-hoc 
test. Graphs show mean ± s.e.m.
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Fig. S1. CPEB status in HD and HD mice. (A, B) CPEB2 and CPEB3 protein 
levels in (A) control or HD striatum, and (B) wild-type or R6/1 mice striatum. (C) 
CPEB1 and CPEB4 protein levels in wild-type or zQ175 mice striatum. (D, E) 
CPEB1 and CPEB4 mRNA levels in (D) control or HD striatum, and (E) wild-type 












Fig. S2. ThTr2 in HD mice. (A, B) SLC19A3 protein (ThTr2) 
levels in (A) wild-type or R6/1 mouse and in (B) wild-type or 
zQ175 brain vessels.
